OmniVis Inc. Selected for Amazon Web Services (AWS) Diagnostic Development Initiative
OmniVis Inc. will receive computing credits and customized expertise from Amazon’s cloud computing arm for a rapid, handheld pathogen detection device.
South San Francisco, CA (January 24, 2022) — OmniVis Inc. today announced it has been selected for the Amazon Web Services (AWS) Diagnostic Development Initiative, a global program focused on accelerating research and innovation to advance the collective understanding and detection of COVID-19 and other infectious diseases.
Through the initiative, AWS provides computing credits and customized expertise from the AWS Professional Services team to support customers using the cloud to drive diagnostic innovations. The initiative supports projects in four program areas: early disease detection, diagnostics, prognosis, and public health genomics.
The support from AWS will advance OmniVis’ efforts to integrate the diagnostic results on their handheld device with a cloud-based epidemiology platform to better monitor disease outbreaks in near real-time.
For real-time outbreak surveillance, we are building a healthcare regulatory compliant cloud-based data portal (hosted on AWS) that is compatible with our diagnostic device. With this support, we will continue to develop our cloud-based portal that shows the GPS location, time stamps, and diagnostic data from the OmniVis device. We will collect data over our field trials and grow the platform to incorporate different diseases and integrate predictive modeling as well.
“With the support of AWS’ Diagnostic Development Initiative, OmniVis can further build out our cloud-based platform and innovate in the diagnostics space,” said Katherine Clayton, co-founder, and CEO of OmniVis Inc. “Since 2020 with the COVID-19 pandemic, we have seen the importance in developing rapid diagnostics and having strong epidemiological evidence to produce scientifically sound public health measures to prevent disease spread. OmniVis is committed to contributing to early pathogen detection and disease monitoring alongside AWS.”
Since its launch in March 2020, the AWS Diagnostic Development Initiative has helped more than 85 organizations around the world, ranging from nonprofits and research institutions to startups and large businesses. AWS intends to distribute $12 million in support this year to organizations worldwide through this program. To learn more, visit www.aws.amazon.com/ddi.
“Cloud-powered diagnostic tools are critical in the fight against COVID-19 and other infectious diseases,” said Maggie Carter, Global Lead, Social Impact at AWS. “Over the last year, AWS has seen inspirational results from the Diagnostic Development Initiative. We look forward to helping OmniVis Inc. and other organizations worldwide use the cloud to mitigate current and future infectious disease outbreaks.”
For more information please contact:
Lotte Vandewalle
Business Operations Manager
+1-415-938-4300
